Related Experiment Videos
Changes in CREB-phosphorylation during recovery from major depression.
Jakob M Koch1, Susanne Kell, Dunja Hinze-Selch
1Department of Psychiatry, Christian-Albrechts-University, Niemannsweg 147, D-24105 Kiel, Germany. jkoch@psychiatry.uni-kiel.de
Journal of Psychiatric Research
|October 24, 2002
Summary
Researchers identified a potential blood test marker for major depression treatment response. Measuring cAMP-response-element-binding-protein (CREB) phosphorylation in T-lymphocytes may predict patient recovery, aiding clinical decisions.
Area of Science:
- Neuroscience
- Molecular Psychiatry
- Biomarker Discovery
Background:
- Major depression lacks reliable biological markers for treatment response prediction.
- Current methods for assessing treatment efficacy are often subjective and delayed.
- Understanding molecular mechanisms of antidepressant action is crucial for personalized medicine.
Purpose of the Study:
- To investigate if CREB phosphorylation in peripheral blood T-lymphocytes serves as a state marker for antidepressant treatment response.
- To determine if changes in CREB phosphorylation correlate with clinical improvement in major depression patients.
- To explore the potential of a blood-based assay for early prediction of treatment outcomes.
Main Methods:
- Assessed CREB phosphorylation at Ser-133 in T-lymphocytes from 20 major depression patients.
- Measurements were taken at baseline, and at the end of weeks one and two of treatment.
- Patients received either psychopharmacological or psychotherapeutic interventions.
- Treatment response was defined as a ≥30% reduction in HAMD score after two weeks.
Main Results:
- Fifteen out of 20 patients (75%) achieved treatment response after two weeks.
- Responders exhibited a significant increase in CREB phosphorylation by week two compared to non-responders (P = 0.018).
- This finding was consistent across both treatment modalities studied.
Conclusions:
- Increased CREB phosphorylation in T-lymphocytes may represent a novel molecular state marker for antidepressant treatment response.
- This blood-based marker could potentially aid in early identification of treatment responders.
- Further validation is warranted to establish CREB phosphorylation as a clinical tool for major depression management.